米非司酮和米索前列醇用于HBV携带者和慢性丙型肝炎患者早孕药物流产安全性评价*

doi:10.3969/j.issn.1672-5069.2016.05.024

Abstract

Bian Qian, Wang Ming, Gao Xiang, et al.. Efficacy and safety of oral mifepristone combined with misoprostol in termination of early pregnancy in individuals with hepatitis B and hepatitis C viral infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 603-604.

References

[1] 李春荣,魏翠荣,程鸾,等. 米非司酮配伍米索前列醇用于过期流产的有效性和安全性分析. 中国现代医学杂志,2010,10（10）：89-90.
[2] Edwards DP,Altmann M,Demarzo A,et al. Progesterone receptor and the mechanism of action of progesterone antagonists. Steroid Biochem,Molec Biol,1995,53（1~6）:449~458.
[3] Ulmann A,Silvestre L,Chemama L,et al. Medical termination of early pregnancy with mifepristone followed by a prostaglandin analogue study in 16000 women. Acta Obstet Gynecol Scand,2002,71（13）：278-283.
[4] 束辉英.米非司酮联合米索前列醇用于人工流产的有效性以及安全性评价. 中国医药科学,2012,2（8）:36-39.
[5] 苗荷,黄桂香. 米非司酮的应用现状. 医学综述,2012,18（6）：912-914.
[6] Kapp N,Borgatta L,Stubblefield P. Mifepristone in second-trimester medical abortion:a randomized controlled trial. Obstet Gynecol,2007,110（6）:1304-1310.
[7] 顾红红,周崇恩,陈卫红. 米索前列醇用于过期流产观察. 中国妇幼保健,2006,21（5）:669.
[8] 邹燕,李幼平,吕琳,等. 药物流产对再次妊娠影响的系统评价. 中国循证医学杂志,2003,3（3）：186-194.
[9] 钟琴琴. 米非司酮的临床运用. 当代医学,2011,17（9）,33-34.
[10] 宋五娥,纪向红,孙聚萍,等. 早期人工流产术中米非司酮配伍米索前列醇的应用. 中国妇幼保健,2004,19（12）:26.
[11] 李满茹,杨秋颖. 米索前列醇在人工流产前应用的临床探讨.中国医药科学,2011,5（1）：84-85.
[12] 袁小嵋. 加大剂量米索前列醇在早期药物流产中的应用. 中国妇幼保健,2006,21（9）：1300-1301.
[13] 王春娣. 米非司酮配伍米索前列醇药物流产150例临床分析.中国医学创新,2011,8（15）：169-170.
[14] 雷贞武. 米非司酮配伍米索前列醇药物流产的安全性问题. 实用妇产科杂志,2009,22（2）：74-75.
[15] 王自能,朱颖媛,卢凤昕. 米非司酮对人胎儿心肌组织超微结构的影响. 暨南大学学报,2000,21（4）：1-3.
[16] 吴尚纯,肖碧莲,刘云荣,等. 米非司酮药物流产使用情况的调查研究. 中国计划生育杂志,1999,46（5）：206-210.
[17] 杨秀琴. 米非司酮流产后血清转氨酶升高.药物不良反应杂志, 2002,4（5）:336-337.

Efficacy and safety of oral mifepristone combined with misoprostol in termination of early pregnancy in individuals with hepatitis B and hepatitis C viral infection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[8]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[9]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[10]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[11]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[12]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[13]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[14]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[15]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.